Author | Jason M. Broderick

Articles

Ide-cel Appears Active in Almost Three-Fourths of Heavily Pretreated Patients with Myeloma

June 06, 2020

ByJason M. Broderick

The BCMA-targeting CAR T-cell therapy yielded a response in73% of patients with heavily pretreated relapsed/refractory multiple myeloma.